Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

Clicks: 403
ID: 266289
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #51 of 443 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 443 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Receiving IFN-free regimens leads to PRO improvement during treatment and after the SVR-12, regardless of OST status. HCV-infected subjects receiving OST did not experience similar PRO improvements with IFN-containing therapy, suggesting that IFN-based therapy may be less suitable for this vulnerabl …
Reference Key
m2018thehepatitis Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stepanova M;Thompson A;Doyle J;Younossi I;de Avila L;Younossi ZM;;
Journal The Journal of infectious diseases
Year 2018
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/29293991
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged drug therapy combination antiviral agents / therapeutic use* ribavirin / administration & dosage ribavirin / therapeutic use chronic / drug therapy* hepacivirus sofosbuvir / therapeutic use pmid:29293991 doi:10.1093/infdis/jix681 maria stepanova alexander thompson zobair m younossi interferons / administration & dosage* interferons / therapeutic use opiate substitution treatment* patient reported outcome measures* sofosbuvir / administration & dosage sustained virologic response

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.